Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Fulcrum Therapeutics' Interest & Investment Income fell 3402.33% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1174.78%. This contributed to the annual value of $12.2 million for FY2024, which is 868.03% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Interest & Investment Income of $2.3 million as of Q3 2025, which was down 3402.33% from $2.5 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Interest & Investment Income high stood at $3.5 million for Q2 2023, and its period low was $34000.0 during Q2 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.4 million (2025), whereas its average is $1.8 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Interest & Investment Income plummeted by 8720.93% in 2021 and then skyrocketed by 441571.43% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Interest & Investment Income (Quarter) stood at $75000.0 in 2021, then skyrocketed by 2350.67% to $1.8 million in 2022, then skyrocketed by 76.06% to $3.2 million in 2023, then dropped by 11.59% to $2.9 million in 2024, then fell by 20.9% to $2.3 million in 2025.
  • Its Interest & Investment Income was $2.3 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.9 million in Q4 2024.